

**MAIN TRAINING COURSES**
**MTC 1-1 HPV: the cause of cervical cancer**

Chair: S. Franceschi

**Forum Hall**
**8:30 – 10:00**

- |  |               |        |
|--|---------------|--------|
| MTC 1-1-1 • Defining new strategies for HPV prevention and control | M. Goodman    | USA    |
| MTC 1-1-2 • The burden of HPV associated diseases                  | S. De Sanjosé | Spain  |
| MTC 1-1-3 • Natural history of HPV infection                       | G. Clifford   | France |
| MTC 1-1-4 • Molecular biology and pathogenesis                     | J. Doorbar    | UK     |
| • Discussion   |               |        |

**Coffee Break 10:00 – 10:30**
**MTC 1-2 Screening and vaccination, new evidence**

Chair: X. Bosch

**Forum Hall**
**10:30 – 12:30**

- |   |             |          |
|---|-------------|----------|
| MTC 1-2-1 • Cervical cancer & cytology based screening programs in Eastern and Central European countries | M. Poljak   | Slovenia |
| MTC 1-2-2 • Overview of HPV assays and molecular markers  | T. Iftner   | Germany  |
| MTC 1-2-3 • New strategies of HPV based screening   | J. Cuzick   | UK       |
| MTC 1-2-4 • HPV vaccination: an update in 2012 (impact – safety – implementation)                         | J. Paavonen | Finland  |
| MTC 1-2-5 • Integration of screening and vaccination in cervical cancer prevention programs               | E. Franco   | Canada   |
| • Discussion  |             |          |

**MTC 1-3 The risk-based management, current knowledge**

Chair: M. Arbyn

**Forum Hall**
**14:00 – 15:30**

- |   |                 |         |
|---|-----------------|---------|
| MTC 1-3-1 • Accuracy of colposcopy                                    | T. Freeman-Wang | UK      |
| MTC 1-3-2 • Triage of ASC-US and L-SIL new evidence                   | W. Huh          | USA     |
| MTC 1-3-3 • HPV and molecular markers in the post-treatment follow-up | M. Arbyn        | Belgium |
| MTC 1-3-4 • Assessing the risk of cervical cancer                     | M. Stoler       | USA     |
| MTC 1-3-5 • Performance and consequences of the treatment of CIN      | M. Cruickshank  | UK      |
| • Discussion  |                 |         |

**Coffee Break 15:30 – 16:00**
**MTC 2 HPV infection and associated diseases in non-cervical sites: facts and figures**

Chair: S. Syrjänen

**Forum Hall**
**16:00 – 17:30**

- |   |             |         |
|---|-------------|---------|
| MTC 2-1 • HPV genital infection and diseases in men                                       | A. Giuliano | USA     |
| MTC 2-2 • Anal neoplasia: burden, epidemiology and prevention                             | J. Palefsky | USA     |
| MTC 2-3 • The HPV cause of head & neck cancers: epidemiology, burden and new developments | M. Gillison | USA     |
| MTC 2-4 • HPV associated diseases in the skin – current knowledge and perspectives        | H. Pfister  | Germany |
| • Discussion  |             |         |

## MAIN TRAINING COURSES

### MTC 3 Decision making in colposcopy

#### MTC 3-1 The fundamentals

Chair: A. Singer – T. Cox

Terrace 1

8:30 – 12:30

- |   |                 |        |
|---|-----------------|--------|
| MTC3-1-1 • Principles of colposcopic examination - nomenclature<br>– performance of colposcopy  | J. Bornstein    | Israel |
| MTC3-1-2 • The normal and abnormal cervix<br>(the TZ concept, the squamous metaplasia, miscellaneous and<br>the abnormal TZ, HPV related lesions, precancerous lesions,<br>the worse features, invasive cancer, ambiguous situations) | A. Singer       | UK     |
| MTC3-1-3 • Glandular lesions – colposcopic features   | T. Freeman-Wang | UK     |
| MTC3-1-4 • Colposcopy in special conditions: pregnancy and menopause  | J. Cortes       | Spain  |

#### Coffee Break 10:00 – 10:30

- |  |                 |           |
|--|-----------------|-----------|
| MTC3-1-5 • Integration of HPV knowledge in colposcopic practice<br>(features, directed biopsies, genotyping) | J. Tan          | Australia |
| MTC3-1-6 • Treatment procedures of CIN   | T. Freeman-Wang | UK        |
| MTC3-1-7 • Issues related to follow-up<br>(cancer following treatment L-SIL, adequate interval of follow-up) | S. Dexeus       | Spain     |
| MTC3-1-8 • Psychological aspects of colposcopy   | D. Harper       | USA       |

#### MTC 3-2 HPV, colposcopy and lower genital tract diseases The best practices and management controversies

Chair: J. Cortes – M. Sideri

Terrace 1

14:00 – 17:00

- Cervix

- |   |                |       |
|---|----------------|-------|
| MTC3-2-1 - The technology (images, video, computer-assistance, storage)   | A. Singer      | UK    |
| MTC3-2-2 - The benefit of taking multiple biopsies  | N. Wentzensen  | USA   |
| MTC3-2-3 - Effects of vaccination on colposcopy   | M. Sideri      | Italy |
| MTC3-2-4 - Cyto & colpo management (ASC-US, ASC-H, L-SIL, H-SIL, AGC)   | W. Huh         | USA   |
| MTC3-2-5 - The outcome of women with a negative colposcopy examination;<br>the perspective from the UK cervical screening programme | M. Cruickshank | UK    |

#### Coffee Break 15:30 – 16:00

- |  |                 |         |
|--|-----------------|---------|
| MTC3-2-6 - HPV results & colpo management (DNA, mRNA, genotyping, p16) | T. Wright       | USA     |
| MTC3-2-7 • Vagina & HPV  | M. Hampl        | Germany |
| MTC3-2-8 • Vulva & HPV   | E. Joura        | Austria |
| MTC3-2-9 • Certification in colposcopy                                 | T. Freeman-Wang | UK      |

#### MTC 3-3 Management scenarios: case studies

Chair: W. Huh – M. Roy

Terrace 1

17:00 – 17:30

- A. Singer (UK)
- J. Tan (Australia)
- M. Roy (Canada)
- J. Cortes (Spain)

**JOINT COURSE OF THE EUROPEAN ACADEMY OF CANCER (EAGC) AND EUROGIN**
**GC Gynecologic Cancer: state of the art**

Coordination: P. Bösze

**Terrace 2**
**9:00 – 17:00**

The major aim of the course is to give an update on some of the important topics on cancer of the female genital tract. This includes surgery for cervical cancer, advances of molecular markers and cancer genetics, treatment guidelines and experience with chemoradiation. The emphasis will be put on both theoretical and practical points.

**GC 1 Chair: P. Bösze – T. Maggino**
**9:00 – 12:30**

- |        |   |              |         |
|--------|---|--------------|---------|
| GC 1-1 | • Introduction  | P. Bösze     | Hungary |
|        |   | S. Dexeus    | Spain   |
| GC 1-2 | • Homage memory to Antonio Onnis                                    | M. Marchetti | Italy   |
| GC 1-3 | • Overview on recent advances in cervical cancer surgical treatment | T. Maggino   | Italy   |
| GC 1-4 | • Step by step clearance of the pelvic side wall                    | L. Pálfalvi  | Hungary |

**Coffee Break 10:05 – 10:30**

- |        |   |             |         |
|--------|---|-------------|---------|
| GC 1-5 | • New horizons in prognostic factors of cervical cancer | K. Syrjänen | Finland |
|--------|---|-------------|---------|

**Free papers**

- |         |   |              |         |
|---------|---|--------------|---------|
| GC 1-6  | • Historical trends in cervical cancer in Greenland: a 60 year overview   | B. Sander    | Denmark |
| GC 1-7  | • Burden of HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 in invasive cervical cancer   | L. Alemany   | Spain   |
| GC 1-8  | • HPV16 viral load and risk of in situ and invasive squamous cervical cancer  | K. Sundström | Sweden  |
| GC 1-9  | • The efficacy of conservative management in patients with cervical cancer stage FIGO IA1 treated with laser CO2 therapy      | S. Tarani    | Italy   |
| GC 1-10 | • Expression of vascular endothelial growth factor (VEGF) in the epithelium and stroma of CIN and invasive cervical carcinoma | LC. Zeferino | Brazil  |
| GC 1-11 | • Biomarkers and associated factors to invasive cervical cancer stage   | A. Nicol     | Brazil  |

**Lunch Break 12:30 – 14:00**
**GC 2 Chair: M. Marchetti – S. Dexeus**
**14:00 – 17:00**

- |        |  |               |                |
|--------|--|---------------|----------------|
| GC 2-1 | • Chemoradiation for cervical cancer   | H. Stankusova | Czech Republic |
| GC 2-2 | • Can we write the epitaph of the cervical cancer? (contribution of the Spanish Association of Cervical Pathology) | S. Dexeus     | Spain          |
| GC 2-3 | • Current knowledge on the management of vulvar cancer   | M. Roy        | Canada         |

**Coffee Break 15:30 – 16:00**

- |        |   |            |                |
|--------|---|------------|----------------|
| GC 2-4 | • Ovarian cancer: new insights              | H. Robova  | Czech Republic |
| GC 2-5 | • Endometrial cancer – the state of the art | P. Bösze   | Hungary        |
| GC 2-6 | • Closing remarks                           | S. Dexeus  | Spain          |
|        |   | T. Maggino | Italy          |

## FREE COMMUNICATIONS

**FC 1 Clinical value of HPV testing**

Chair: J. Jeronimo – M. Elfström

Klub D (Level 1)

8:30 – 10:00

FC 1-1	• HPV genotyping and cofactors in the detection of high-risk patients after conisation	G. Hoste	Belgium
FC 1-2	• High-risk human papillomavirus E6/E7 mRNA and L1 DNA as markers of residual/recurrent cervical intraepithelial neoplasia	M. Persson	Sweden
FC 1-3	• E6 testing for primary screening or triage evaluation: experience from China	J. Jeronimo	USA
FC 1-4	• Performance of two HR HPV-mRNA detection tests on Thin-Prep samples from HPV-DNA positive women selected for colposcopic examination	C. Matinato	Italy
FC 1-5	• HPV-DNA titres in squamous cervical intraepithelial lesions (SIL): correlation with lesion severity and viral findings	B. Dal Bello	Italy
FC 1-6	• Cervista HPV HR performance evaluation using samples collected in SurePath preservative fluid	M. Olson	USA
FC 1-7	• Histologic comparison of cervical biopsies in ASCUS/HPV-HR diagnosed patients	A. Dierick	Belgium
FC 1-8	• Comparison of HPV OncoTect and nucliSENS Easy q test in preneoplastic lesions of the cervix	F. Papa	Italy
FC 1-9	• Type-dependent E6/E7 mRNA expression of single and multiple HR-HPV infections in cervical neoplasia	E. Andersson	Sweden

Coffee Break 10:00 – 10:30

**FC 2 HPV testing methods**

Chair: J.-P. Bogers – B. Hesselink

Klub D (Level 1)

10:30 – 12:30

FC 2-1	• Stability of cervical specimens collected in SurePath® preservative fluid for use with cobas® 4800 HPV test	L. Gilbert	Canada
FC 2-2	• Impact of the urine fraction (first-void versus mid-stream) on HPV DNA detection	A. Vorsters	Belgium
FC 2-3	• HPV mRNA in cervical and vaginal samples from an APTIMA collection and transportation kit	M. Chernesky	Canada
FC 2-4	• Comparison of HPV testing methods: HPV DIRECT FLOW CHIP, Linear Array, Genomica Clart HPV2 and Hybrid Capture 2	A. Olmo	Spain
FC 2-5	• The internal control in the Cervista HPV HR assay identifies clinical specimens with insufficient cellularity	K. Youens	USA
FC 2-6	• Comparison of self-collected cervical specimen and gynecologist-collected cervical specimen for detection of human papillomavirus DNA	Z. Ibrahim	Malaysia
FC 2-7	• Randomized comparison of vaginal self-sampling for HPV testing by standard vs. dry vaginal swabs	D. Pirek	Switzerland
FC 2-8	• Correlation of high risk HPV detection with liquid-based cytology and clinical outcome in a German routine setting - comparison of RealTime High Risk HPV and Hybrid Capture 2	H. Ikenberg	Germany
FC 2-9	• Can SurePath™ fixative, used for fixation of cervical biopsies be a substitute for paraffin sections in HPV-genotyping by Papillocheck®?	H. Pedersen	Denmark
FC 2-10	• Cervista HPV HR assay. Birmingham city hospital experience using Hologic HPV platform in a routine cytology laboratory	D. Edwards	UK
FC 2-11	• Comparison of the F-HPV typing™ and Hybrid Capture 2® assays for detection of high-risk HPV genotypes in cervical samples	V. Cirigliano	Spain
FC 2-12	• Comparison of INNO-LiPA HPV genotyping extra assay and Abbott RealTime high-risk HPV test on three different cervical collection media for HR HPV detection	S. Hantz	France
FC 2-13	• Analytical performance of HPV direct flow chip compared with sequencing analysis	E. Herraes-Hernandez	Spain

## WACC (Women Against Cervical Cancer)

### W 1 Sharing knowledge & education for cervical cancer prevention

Chair: J. Smith – M. Steben

Klub D (level 1)

14:00 – 15:30

- |        |  |                            |                    |
|--------|--|----------------------------|--------------------|
| W 1-1  | • Lecture: 2011 UN declaration on the importance of non-communicable diseases (breast, cervix)   | A. Ullrich                 | Switzerland        |
| W 1-2  | • Barriers to screening in sexually active women in developed countries and in low and middle income countries                                 | L. Cadman                  | UK                 |
| W 1-3  | • Centers of Excellence as a need for improving cervical cancer prevention in low-resources settings   | J. Jeronimo                | USA                |
| W 1-4  | • Polish coalition against cervical cancer – a strong call for real change   | M. Stelmach                | Poland             |
| W 1-5  | • Health care databases – a tool to study population effects of HPV vaccination: assessment of HPV vaccination in German health insurance data | J. Horn<br>R. Schulze-Rath | Germany<br>Germany |
| W 1-6  | • Coverage and compliance of human papillomavirus vaccines in Franche-Comté  | A. Baudu                   | France             |
| W 1-7  | • HPV vaccine acceptability in adult Japanese women: does experience with HPV-related conditions matter?                                       | S. Hanley                  | Japan              |
| W 1-8  | • Pharmacist vaccination authority of the human papillomavirus vaccine: a state-by-state analysis of the United States of America              | J. Chung                   | USA                |
| W 1-9  | • Colposcopy and cervical pathology education in Russia  | S. Rogovskaya              | Russia             |
| W 1-10 | • Awareness of HPV, cervical cancer and HPV vaccine in Turkey, attitudes from a Muslim country   | N. Güdücü                  | Turkey             |
| W 1-11 | • Knowledge and health beliefs among Syrian health workers about cervical cancer prevention and early detection                                | D. Al-Khoury               | Syria              |
| W 1-12 | • Risk and preventive behaviours amongst HPV vaccinated and unvaccinated young women   | L. Sadler                  | UK                 |

Coffee Break 15:30 – 16:00

### W 2 Science facing false ideas: how to deal with anti-vaccine groups

Chair: J. Cain – R. Konno

Klub D (level 1)

16:00 – 17:30

- |       |  |              |        |
|-------|--|--------------|--------|
| W 2-1 | • Benefits vs risk of HPV vaccines   | P.L. Lopalco | Sweden |
| W 2-2 | • Side effects are they of concerns?   | S. Garland   | USA    |
| W 2-3 | • Cost effectiveness issues – are they questionable?   | M. Brisson   | Canada |
| W 2-4 | • Ethical issues of HPV vaccine information, is there any deviation?   | J. Cain      | USA    |
| W 2-5 | • Conclusion: why do we need a broad HPV vaccine program to prevent cervical cancer in developed and developing countries? | E. Franco    | Canada |



## OPENING CEREMONY

Forum Hall

Sunday, July 8

19:00

**Welcome Address**

*J. Monsonego*

19:05 - 19:20

**Presidential Messages**

*X. Bosch (Spain)*

*S. Syrjänen (Finland)*

*S. Franceschi (France)*

19:25

**Homage Memory to John Sellors**

*L. Elit (USA)*

19:30 - 20:00

**Opening lecture**

**Safety issues associated to HPV vaccination,  
looking back and forward**

*C.A. Siegrist (Switzerland)*

20:00 - 21:15

**Welcome Cocktail**

*Zoom Restaurant at level 1*

**MAIN SCIENTIFIC SESSIONS**
**MSS 1 HPV and non-genital human cancers: new challenges**

Chair: M. Gillison – K. Syrjänen

**Forum Hall**
**8:00 – 9:30**

MSS 1-1 • HPV-associated cancers – a growing problem?	M. Stanley	UK
MSS 1-2 • HPV and oropharyngeal cancer: current knowledge	L. Licitra	Italy
MSS 1-3 • Current management of head & neck cancer	H. Mehanna	France
MSS 1-4 • The role of papillomavirus infection in skin cancer development	J.N. Bouwes-Bavinck	The Netherlands
MSS 1-5 • HPV, oesophagus & lung: what evidence?	K. Syrjänen	Finland
MSS 1-6 • The significance of HPV in the colon & rectum	L. Lorenzon	Italy

**MSS 2 HPV vaccines – update and perspectives**

Chair: J. Paavonen – M. Stanley

**Forum Hall**
**9:30 – 11:00**

MSS 2-1 • Introduction: evidence on efficacy of HPV vaccines	J. Paavonen	Finland
MSS 2-2 • Current knowledge on safety profile of the current HPV vaccines	P.L. Lopalco	Sweden
MSS 2-3 • Global impact of HPV vaccination in men & women	M. Brisson	Canada
MSS 2-4 • A second-generation broad-spectrum HPV vaccine	C. Schellenbacher	Austria
MSS 2-5 • The prospects for an L2 based prophylactic vaccine	P. Stern	UK
MSS 2-6 • Therapeutic vaccines	S. Pai	USA

**Coffee Break 11:00 – 11:30**

## WORKSHOPS

**WS 1 Cervical cancer and human papillomavirus in Central and Eastern Europe**

Chair: G. Lazdane

**North Hall****8:00 – 11:00**

WS 1-1	• Overview: current situation in Eastern European countries	G. Lazdane	Denmark
WS 1-2	• Current status of cervical cancer screening and HPV vaccination implementation in Slovenia	M. Poljak	Slovenia
WS 1-3	• Cervical cancer in the Slovak Republic: an overview on actual situation in incidence, mortality, screening and vaccination	P. Zubor	Slovak Republic
WS 1-4	• Primary and secondary prevention of cervical cancer in Poland. The proposal of new diagnostic methods	W. Rokita	Poland
WS 1-5	• The epidemiology of the cervical cancer and HPV infections in Poland	E. Nowak-Markwitz	Poland
WS 1-6	• The Polish Coalition Against Cervical Cancer, what worked?	R. Poreba	Poland
WS 1-7	• HPV prevention and cervical cancer control in Bulgaria – current recommendations and perspectives	M. Kojouharova	Bulgaria
WS 1-8	• Cervical cancer screening program in Latvia	I. Viberga	Latvia
WS 1-9	• Cervical cancer prevention in the Czech Republic – how to start just in time	J. Bogdanova	Czech Republic
WS 1-10	• Concentration of selected biochemical parameters in blood of pregnant women infected by HPV 16 and 18	A. Karowicz	Poland

**WS 2 Программа Российской Сессии на Конгрессе EUROGIN в Праге Regional Workshop: Russia**

Председатели: академик Сухих Г.Т., проф. Прилепская В.Н,  
проф. Подзолкова Н.М., проф. Урманчеева А.Ф  
Coordination: V. Prilepskaya – I. Shabalova

**Terrace 1****8:00 – 11:00***This workshop is held in Russian language only.*

WS 2-1	• Современное состояние и перспективы скрининга <i>Current screening situation and perspectives</i>	Проф. Шабалова И.П. I. Shabalova
WS 2-2	• Вакцинация против ВПЧ и цервикального рака. Состояние проблемы в России <i>Vaccination against HPV and cervical cancer. State of the problem in Russia</i>	Ак. Сухих Г.Т., проф. Прилепская В.Н. G. Sukhikh, V. Prilepskaya
WS 2-3	• Роль образования врачей и населения в профилактике рака шейки матки <i>The role of physicians and the public education in cervical cancer prevention</i>	Проф. Подзолкова Н.М. N. Podzolkova
WS 2-4	• Цитологический скрининг глазами цитолога <i>Cytological screening – a look of cytologist</i>	Проф. Шабалова И.П. I. Shabalova
WS 2-5	• Роль ВПЧ теста в ведении патологии шейки матки <i>The role of HPV testing in management of cervical pathology</i>	Проф. Роговская С.И. S. Rogovskaya
WS 2-6	• Диагностическая и прогностическая значимость онкобелков Е6 и Е7 при цервикальной интраэпителиальной неоплазии (CIN) <i>Diagnostic and prognostic significance of tumor markers E6 and E7 in cervical intraepithelial neoplasia (CIN)</i>	Проф. Ашрафян Л.А. L. Ashrafyan
WS 2-7	• Роль кольпоскопии в диагностике заболеваний ассоциированных с ВПЧ <i>Colposcopy role in the diagnosis of diseases associated with HPV</i>	Д-р Костава М.Н. M. Kostava
WS 2-8	• Менеджмент пациенток с CIN <i>Management of patients with cervical intraepithelial neoplasia (CIN)</i>	Проф. Минкина Г.Н. G. Minkina
WS 2-9	• Менеджмент пациенток с микрокарциномой (CIS) <i>Management of patients with microcarcinoma (CIS)</i>	Проф. Козаченко В.П. V. Kozachenko
WS 2-10	• Рак шейки матки и беременность <i>Cervical cancer and pregnancy</i>	Проф. Урманчеева А.Ф. A. Urmancheeva
	• Дискуссия Discussion	

**Coffee Break 11:00 – 11:30**



## FREE COMMUNICATIONS

### FC 3 From HPV infection to diseases

Chair: S. De Sanjosé – P. Sparen

Panorama Hall (level 1)

8:00 – 11:00

- |         |  |                  |                 |
|---------|--|------------------|-----------------|
| FC 3-1  | <ul style="list-style-type: none"> <li>• Prediction of cervical intraepithelial neoplasia of grade 2+ (CIN2+) using HPV DNA testing in the regular cervical screening activities of the national health service in Catalonia, Spain</li> </ul> | S. De Sanjosé    | Spain           |
| FC 3-2  | <ul style="list-style-type: none"> <li>• Expressed prostate secretions (EPS) for the study of the epidemiology of HPV infections in the male</li> </ul>  | V. Smelov        | Sweden          |
| FC 3-3  | <ul style="list-style-type: none"> <li>• Population-based HPV prevalence, genotype distribution and risk-factors for HPV infection in 20-25-year-old women in Germany</li> </ul>   | Y. Deleré        | Germany         |
| FC 3-4  | <ul style="list-style-type: none"> <li>• HPV in young women in Germany – a population based epidemiological study</li> </ul>   | A. Luyten        | Germany         |
| FC 3-5  | <ul style="list-style-type: none"> <li>• Age-specific prevalence of cervical HPV infection and cytological abnormalities in women in Gauteng, South Africa</li> </ul>  | K. Richter       | South Africa    |
| FC 3-6  | <ul style="list-style-type: none"> <li>• Human papillomavirus genotype distribution in cervical intra-epithelial neoplasia: a prospective study from 2008-2011 in Belgium</li> </ul>   | M. Vandecasteele | Belgium         |
| FC 3-7  | <ul style="list-style-type: none"> <li>• Epidemiological study of high-risk HPV in Midi-Pyrénées (France) with Abbott high-risk HPV RealTime PCR in 2011</li> </ul>  | M. Bernier       | France          |
| FC 3-8  | <ul style="list-style-type: none"> <li>• Age-specific distribution of HPV infection among young females in Italy</li> </ul>  | S. Corioni       | Italy           |
| FC 3-9  | <ul style="list-style-type: none"> <li>• HPV infection and genotypes' distribution in cervical cancer in Saudi Arabia: implication for screening and prevention</li> </ul>   | G. Alsbeih       | Saudi Arabia    |
| FC 3-10 | <ul style="list-style-type: none"> <li>• High-risk human papillomavirus genotype frequency among Brazilian samples</li> </ul>  | N. Gaburo        | Brazil          |
| FC 3-11 | <ul style="list-style-type: none"> <li>• Seroprevalence of HPV-16 and -18 among heterosexual men, women and men who have sex with men, attending an STI clinic in The Netherlands</li> </ul>   | C.J. Alberts     | The Netherlands |
| FC 3-12 | <ul style="list-style-type: none"> <li>• Seroprevalence and determinants of high-risk HPV types in HIV-infected and HIV-negative men who have sex with men</li> </ul>  | S. Mooij         | The Netherlands |
| FC 3-13 | <ul style="list-style-type: none"> <li>• Role of contraception in the evolution of high-risk human papillomavirus infections and cervical intraepithelial neoplasia</li> </ul>   | K. Vossaert      | Belgium         |

**Coffee Break 11:00 – 11:30**

## MAIN SCIENTIFIC SESSIONS

### MSS 3 HPV based screening strategies: current knowledge

Chair: T. Wright – J. Cuzick

Forum Hall

14:00 – 15:30

MSS 3-1 • Cytology with triage by HPV testing	G. Ronco	Italy
MSS 3-2 • Triage strategies for HPV positive women	H. Berkhof	The Netherlands
MSS 3-3 • HPV genotyping based screening- new evidence	M. Stoler	USA
MSS 3-4 • HPV mRNA in primary screening	T. Iftner	Germany
MSS 3-5 • Role of p16 in screening	F. Carozzi	Italy
MSS 3-6 • Methylation as a screening marker	A. Lorincz	UK
MSS 3-7 • HPV screening in low resource settings	R. Sankaranarayanan	France
MSS 3-8 • Conclusion: what the clinicians should know	W. Huh	USA

### MSS 4 New screening experiences and HPV vaccine implementation: lessons learned & actions

Chair: P. Sasieni– N. Broutet

Forum Hall

15:30 – 17:00

#### 1. New HPV screening experiences

MSS 4-1 • The Netherlands	H. Berkhof	The Netherlands
MSS 4-2 • Italy	G. Ronco	Italy
MSS 4-3 • Low resource settings	J. Jeronimo	USA

#### 2. HPV vaccine implementation: countries deliberation

MSS 4-4 • England	K. Soldan	UK
MSS 4-5 • France	I. Parent du Chatelet	France
MSS 4-6 • Italy	P. Bonanni	Italy
MSS 4-7 • Australia	C. Selvey	Australia
MSS 4-8 • Eastern European countries	G. Lazdane	Denmark
MSS 4-9 • The role of the GAVI Alliance in worldwide implementation of HPV vaccination	N. Schwalbe	Switzerland

#### 3. HPV vaccine and Babel Tower: round table – changes & impact in screening policies

##### Clinicians' point of view

MSS 4-10 • The gynecologist	J. Paavonen	Finland
MSS 4-11 • The pediatrician	F. Martinon Torres	Spain
MSS 4-12 • The GP	M. Steben	Canada

##### Public health representatives' point of view

MSS 4-13 • WHO	N. Broutet	Switzerland
MSS 4-14 • ECDC	P.L. Lopalco	Sweden
MSS 4-15 • FIGO	J. Cain	USA

Coffee Break 17:00 – 17:30

## SEMINARS

### SEM 1 Head & neck cancer and HPV co-organized by EUROGIN & EHNS

Coordination: H. Mehanna – J.-L. Lefebvre

North Hall

14:00 – 17:00

Oropharyngeal cancer is one of the fastest rising cancers in many countries. This has been attributed to the rise in HPV-head and neck cancer. This new disease entity appears to have significantly better survival outcomes. However, important questions arise regarding its natural history, diagnosis, patient counselling and the best management regimens.

SEM 1-1 • The burden of head & neck cancer and the changing risk factors	J.L. Lefebvre	France
SEM 1-2 • The epidemiology and burden of HPV-oropharyngeal cancer	H. Mehanna	France
SEM 1-3 • Molecular carcinogenesis of HPV+ and HPV- head & neck cancer	R. Brakenhoff	The Netherlands
SEM 1-4 • Effect of HPV on survival in head & neck cancer	M. Gillison	USA
SEM 1-5 • Oral HPV infection, its epidemiology, transmission and significance among spouses	S. Syrjänen	Finland
SEM 1-6 • The potential value of screening & vaccination	A. Chaturvedi	USA
SEM 1-7 • Biological correlates of HPV positivity in cervical and oropharyngeal HPV tumors	M. Gillison	USA
SEM 1-8 • Prognostic factors of HPV positive cases and serological markers in follow up	J. Klozar	Czech Republic
SEM 1-9 • The challenges of prospective research in oropharyngeal cancer	H. Mehanna	France
SEM 1-10 • Therapeutic vaccination in HPV head & neck cancer – fact or fiction?	S. Pai	USA

#### 1. What are the available treatments for HPV head & neck cancer

SEM 1-11 • a - Surgical treatment options for oropharyngeal cancer (Open surgery and transoral laser or robotic surgery)	J.L. Lefebvre	France
SEM 1-12 • b - Chemoradiotherapy	L. Licitra	Italy

#### 2. Diagnostic clinical service for HPV head & neck cancer

SEM 1-13 • a - Setting up a diagnostic service for HPV head & neck cancer	T. Dalianis	Sweden
SEM 1-14 • b - Pitfalls in the diagnosis of HPV in head & neck cancer	P. Snijders	The Netherlands

#### 3. Screening for oral and oropharyngeal cancer

SEM 1-15 • For	R. Sankaranarayanan	France
SEM 1-16 • Against	J. Lacau de St. Guily	France

Coffee Break 17:00 – 17:30

## SEMINARS

## SEM 2 HPV in dermatovenereology

co-organized by EUROGIN and EADV (European Academy of DermatoVenereology) HPV Task Force

Coordination: G. Gross, J. Hercogová, H. Pfister, M. Skerlev

Terrace 1  
14:00 – 17:00

HPV is definitely involved in the origin and development of genitoanal cancer of both genders (cervical cancer, vulval cancer, vaginal cancer, anal cancer and penile cancer).

HPV types from the betapapillomaviruses (betaPV) genus may play a role in cutaneous squamous cell carcinoma. Functional data support a potential role for betaPV as cocarcinogens with UV, but with mechanisms likely to differ fundamentally to those established in anogenital cancer. HPV-specific antiviral agents are not currently available, but therapeutic anti-HPV vaccines are in development and would be especially appropriate for those persons for whom we can predict a high-risk of multiple squamous cell carcinoma. Cutaneous squamous cell carcinomas are an eminent clinical problem in the management of immunosuppressed organ transplant recipients.

### Part I - External genitalia and HPV associated diseases

SEM 2-1 • Epidemiology and burden of genital warts	S. Garland	Australia
SEM 2-2 • Epidemiology and burden of VIN	J. Bornstein	Israel
SEM 2-3 • Management: genital warts	G. Gross	Germany
SEM 2-4 • Management: VIN	M. Hampl	Germany
SEM 2-5 • Prevention	A. Giuliano	USA

### Part II - Skin

SEM 2-6 • Epidemiology of papillomavirus infection and skin cancer in organ transplant recipients	J.N. Bouwes-Bavinck	The Netherlands
SEM 2-7 • Skin cancer in immunosuppressed patients	J. Hercogova	Czech Republic
SEM 2-8 • Molecular mechanisms of keratinocyte transformation	M. Tommasino	France
SEM 2-9 • Skin cancer development in beta-HPV transgenic mice	H. Pfister	Germany
SEM 2-10 • HPV – skin deep and beyond	M. Skerlev	Croatia
• Discussion - Round table		

Coffee Break 17:00 – 17:30

## SEM 3 Anal HPV associated diseases

Coordination: J. Palefsky – P. Mullerat

Panorama Hall (level 1)  
14:00 – 17:00

The incidence of AIN (anal intraepithelial neoplasia) and anal squamous cell carcinoma (SCC) is increasing. Their relationship with HPV is unquestionable. Anal SCC is more prevalent in homosexual males and amongst immunosuppressed groups. The incidence, natural history, risk factors of progression, and best treatment are largely unknown. Early diagnosis and clinical awareness will prevent mutilating surgery.

SEM 3-1 • Burden - Epidemiology	A. Grulich	Australia
SEM 3-2 • The natural history of anal HPV infection and disease	C. Lacey	UK
SEM 3-3 • Anatomy of the anal canal - AIN screening - HPV & AIN	P. Mullerat	UK
SEM 3-4 • Management of AIN and anal cancer	L. Siproudhis	France
SEM 3-5 • Anal HPV infection and its consequences: prevention & perspectives	J. Palefsky	USA

Coffee Break 17:00 – 17:30

**MAIN SCIENTIFIC SESSIONS**
**MSS 5 Hot topics on HPV infection and diseases  
Exchanging points of view with the experts  
and public health representatives**

Chair: E. Franco – J. Peto

**Forum Hall**
**8:00 – 10:00**

- |   |            |             |
|---|------------|-------------|
| MSS 5-1 • Lecture: combining HPV vaccination and HPV screening in older women: is it rational?                              | J. Peto    | UK          |
| <b>1. Doubt out: the ultimate debate on HPV vaccines</b>  |            |             |
| MSS 5-2 • Reduced / alternative vaccine dose schedules  | M. Steben  | Canada      |
| MSS 5-3 • The comparative value of bivalent & quadrivalent vaccines   | M. Jit     | UK          |
| <b>2. HPV screening controversies: controversies from the updated guidelines on cervical cancer screening – round table</b> |            |             |
| MSS 5-4 • Introduction: current barriers to implement HPV screening   | E. Franco  | Canada      |
| MSS 5-5 • Perspectives of an organized program on the inclusion of HPV testing in cervical cancer screening                 | J. Dillner | Sweden      |
| MSS 5-6 • EU  | M. Arbyn   | Belgium     |
| MSS 5-7 • WHO   | N. Broutet | Switzerland |
| MSS 5-8 • FIGO  | J. Cain    | USA         |
| <b>3. Moving forward in comprehensive screening and vaccination programs</b>  |            |             |
| MSS 5-9 • Concepts for a European implementation trial  | X. Bosch   | Spain       |

**MSS 6 Advanced topics on screening and vaccination**

Chair: P. Bonanni – X. Bosch

**Forum Hall**
**10:00 – 11:15**

- |   |            |             |
|---|------------|-------------|
| MSS 6-1 • LBC variability of baseline results from different ATHENA sites   | T. Wright  | USA         |
| MSS 6-2 • Monitoring of HPV vaccination effects in Sweden   | J. Dillner | Sweden      |
| MSS 6-3 • SEHIB study: surveillance of effects of HPV immunization in Belgium   | S. Weyers  | Belgium     |
| MSS 6-4 • Decision by GAVI Alliance to include HPV vaccine in roster of vaccines subsidized for world's poorest countries | K.D. Aung  | Switzerland |
| MSS 6-5 • Optimization of screening & vaccination by modeling   | M. Jit     | UK          |
| MSS 6-6 • Vaccine impact in Australia and the need to review screening  | C. Selvey  | Australia   |

## SCIENTIFIC SESSIONS

<b>SS 1</b>	<b>Recent advances on cervical cancer screening</b> Chair: G. Ronco – N. Wentzensen	<b>North Hall</b> <b>8:00 – 9:30</b>	
SS 1-1	• Screening interval: co-testing vs cytology, a 5 year analysis	T. Cox	USA
SS 1-2	• Will cytology with adjunctive staining for p16/Ki67 make HPV testing superfluous in cervical cancer screening?	G. Ronco	Italy
SS 1-3	• Randomised implementation of primary HPV screening in Sweden	C. Eklund	Sweden
SS 1-4	• Screening intervals in HPV negative women	M. Elfström	Sweden
SS 1-5	• VIA vs HPV based screening in developing countries	R. Sankaranarayanan	France
SS 1-6	• Methylation markers for the triage of HPV positive women	N. Wentzensen	USA
<b>SS 2</b>	<b>Advantages and barriers to self-sampling HPV screening</b> Chair: J. Belinson – J. Bornstein	<b>North Hall</b> <b>9:30 – 11:00</b>	
SS 2-1	• HPV detection in self-collected vaginal specimen in Sweden	U. Gyllensten	Sweden
SS 2-2	• A new paradigm for cervical cancer screening based on self-sampling	J. Belinson	USA
SS 2-3	• HPV testing in non-attendeeds of cervical screening	D. Heideman	The Netherlands
SS 2-4	• Molecular triage of HPV positive women in self-sampled material	B. Hesselink	The Netherlands
SS 2-5	• Self-collection for care HPV testing: results from multi-country experiences	J. Jeronimo	USA
SS 2-6	• Self-collection of vaginal specimens for HPV testing in cervical cancer prevention: the MARCH trial	A. Lorincz	UK

Coffee Break 11:00 – 11:30

## SCIENTIFIC SESSIONS

### SS 3 Advanced topics in epidemiology

Chair: A. Giuliano – S. de Sanjosé

Terrace 1

8:00 – 9:30

- |        |   |               |                  |
|--------|---|---------------|------------------|
| SS 3-1 | • Burden of cervical cancer in Europe – Western vs Eastern European countries | E. Weiderpass | Vainio<br>Norway |
| SS 3-2 | • Survival from screen-detected vs symptomatic cervical cancer                | B. Andrae     | Sweden           |
| SS 3-3 | • Susceptible populations   | G. Clifford   | France           |
| SS 3-4 | • Cervical cytokines and HPV clearance  | M. Goodman    | USA              |
| SS 3-5 | • Redetection of HPV: reactivation vs latency                                 | A.B. Moscicki | USA              |
| SS 3-6 | • Comparative epidemiology HPV infection in men & women                       | A. Giuliano   | USA              |
| SS 3-7 | • HPV infection in immigrant population                                       | P. Sparen     | Sweden           |

## FREE COMMUNICATIONS

### FC 4 Diagnosis and management

Chair: M. Cruickshank – D. Harper

Terrace 1

9:30 – 11:15

- |         |   |                   |                 |
|---------|---|-------------------|-----------------|
| FC 4-1  | • The impact of HPV genotype on the performance of colposcopy in young women  | M. Cruickshank    | UK              |
| FC 4-2  | • Management of adenocarcinoma in situ of the uterine cervix using an outpatient loop excisional procedure  | G. Machado        | Brazil          |
| FC 4-3  | • HPV E6/E7 mRNA and HPV DNA testing in post colposcopic treatment surveillance of cervical intraepithelial neoplasia   | C. Martin         | Ireland         |
| FC 4-4  | • HPV16 genome methylation as biomarker in cervical adenocarcinoma and oropharynx carcinoma   | D. Barbieri       | Italy           |
| FC 4-5  | • Conservative treatment of microinvasive adenocarcinoma (MIAC) of the cervix: the prognostic significance of clearance apex in the cone biopsy                                   | F. Sopracordevole | Italy           |
| FC 4-6  | • Accuracy of Pap and Bethesda oncocytology for prediction of CIN3+ in women with squamous intraepithelial lesions indicated for conisation: correlation with histologic findings | P. Zubor          | Slovak Republic |
| FC 4-7  | • Combined condylomatosis and buschke-loewenstein tumor: case report & systematic rev   | O. Mynbaev        | Russia          |
| FC 4-9  | • Application of telectyology for Pap smears diagnostic   | E. Kldiashvili    | Georgia         |
| FC 4-10 | • Condyloma accuminatum vs. condyloma latum: similar name, different disease  | Z. Kruzicova      | Czech Republic  |
| FC 4-11 | • Automated detection of cervical dysplasia through holographic digital microscopy using laser light. An objective classification on 3-dimensional cell information               | O. Magniette      | Belgium         |

## FREE COMMUNICATIONS

**FC 5 Molecular markers**

Chair: C. Depuydt – M. Tommasino

Klub E (level 1)

8:00 – 9:30

- |        |  |               |                 |
|--------|--|---------------|-----------------|
| FC 5-1 | • Amplification of the chromosome 3q26 region in liquid cytology specimens as a marker for clearance of lesion post-treatment in cervical cancer | C. Depuydt    | Belgium         |
| FC 5-2 | • A systematic review of chromosomal gains and losses in lower genital tract lesions   | L. Thomas     | Germany         |
| FC 5-3 | • Value of a novel panel of cellular biomarkers in cervical cancer screening and triage  | C. Jeney      | Hungary         |
| FC 5-4 | • HPV16 early transcript expression is not necessarily regulated by integration in cervical smears, the role of DNA methylation                  | E. Jacquin    | France          |
| FC 5-5 | • Distinct HPV 16 URR methylation in permissive and transforming infections  | S. Vinokurova | Germany         |
| FC 5-6 | • Amplification of TERT and TERC genes in cytology samples from cervical cancer and cervical intraepithelial neoplasias                          | E. Kudela     | Slovak Republic |
| FC 5-7 | • The p16 <sup>INK4A</sup> and E6 mRNA quantitative expression in cervical squamous lesions from patients with HPV 16/18 infection               | V. Janusicova | Slovak Republic |

**FC 6 HIV/STI and HPV infections**

Chair: C. Lacey – K. D'Hauwers

Klub E (level 1)

9:30 – 10:30

- |        |   |                            |                                  |
|--------|---|----------------------------|----------------------------------|
| FC 6-1 | • HPV prevalence & abnormal cytology in HIV-seropositive women from HIV-discordant couples                            | J.A. Cooper                | USA                              |
| FC 6-2 | • Prospective evaluation of cervical screening methods in HIV positive women in Africa (HARP study): baseline results | H. Kelly                   | UK                               |
| FC 6-3 | • Cervical and anal HPV detection among women drug users living with HIV in Miami, Florida                            | I. Rosa-Cunha              | USA                              |
| FC 6-4 | • Clinical relevance of sexual transmitted disease profile and human papillomavirus (HPV) infection in Thai females   | K. Nuttavut                | Thailand                         |
| FC 6-5 | • HPV flare in HIV patient  | D. Vanousova<br>L. Machala | Czech Republic<br>Czech Republic |

**FC 7 Anal HPV diseases**

Chair: L. Siproudhis – P. Mullerat

Klub E (level 1)

10:30 – 11:30

- |        |   |                   |                 |
|--------|---|-------------------|-----------------|
| FC 7-1 | • Joint biomarkers in HPV16 invasive anal carcinoma   | C. Mougin         | France          |
| FC 7-2 | • Predictive factors for anal HPV prevalence in HIV negative women: patients visiting a colposcopy-clinic versus sex workers                                  | K. D'Hauwers      | The Netherlands |
| FC 7-3 | • Evaluation of HR-HPV mRNA and p16/Ki67 testing in screening for anal intraepithelial neoplasia in HIV infected patients                                     | C. Dupin          | France          |
| FC 7-4 | • Pain and bleeding associated with anal cancer screening strategies in homosexual men  | D. Templeton      | Australia       |
| FC 7-5 | • Risk factors for anal HPV infection in patients with severe cervical dysplasia  | B. Sehnal         | Czech Republic  |
| FC 7-6 | • HPV genotype prevalence in anal specimens among HIV-positive men who have sex with men (MSM): can HPV vaccination help to prevent anal HPV-related lesions? | S. Villar del Saz | Spain           |



## MAIN SCIENTIFIC SESSIONS

### MSS 7 EUROGIN 2012 Roadmap Cervix and head & neck HPV associated cancers: towards comparative insights

Chair: S. Franceschi – M. Gillison

**Forum Hall**

**14:00 – 15:30**

#### 1. Epidemiologic comparison of cervical cancer and HPV associated head and neck cancer

MSS 7-1 • Similarities and differences in the epidemiology of HPV infection (cervical vs. oral)

A. Chaturvedi USA

MSS 7-2 • Similarities and differences in the epidemiology of cancer

X. Castellsagué Spain

MSS 7-3 • Similarities and differences between cancer of the cervix and the upper aerodigestive tract

S. Franceschi France

#### 2. Molecular comparison of cervical cancer and HPV associated head and neck cancer

MSS 7-4 • Mechanisms of carcinogenesis

M. Tommasino France

MSS 7-5 • What HPV types should be considered high-risk/oncogenic? Type-specificity of cancer risk

M. Goodman USA

#### 3. Comparison of clinical and prevention aspects of cervical cancer and HPV associated head and neck cancer

MSS 7-6 • Clinical value of testing for HPV infection and additional markers  
Netherlands

P. Snijders The

MSS 7-7 • Potential for primary and secondary prevention through HPV vaccination and screening

M. Gillison USA

### MSS 8 New promising strategies using HPV DNA and mRNA testing

Chair: T. Iftner – M. Poljak

**Forum Hall**

**15:30 – 16:30**

MSS 8-1 • Clinical validation of HPV DNA tests in cervical screening

D. Heideman The Netherlands

MSS 8-2 • Risk assessment and clinical impact of 3 HPV assays in cervical cancer screening – the FASE study

J. Smith USA

MSS 8-3 • HPV primary screening compared to co-testing: estimates of efficacy vs. efficiency using the COBAS HPV test

M. Stoler USA

MSS 8-4 • HPV focal: first round screen results from a Canadian population based program

E. Franco Canada

MSS 8-5 • The APTIMA HPV assay versus the Hybrid Capture II test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy

M. Arbyn Belgium

**Coffee Break 16:30 – 17:00**

## MAIN SCIENTIFIC SESSIONS

### MSS 9 The emerging role of genotyping

Chair: M. Stoler – K. Cuschieri

Forum Hall

17:00 – 18:00

MSS 9-1 • LSIL age stratification (ATHENA baseline data)	J. Cuzick	UK
MSS 9-2 • Meta-analysis HPV16-18 in triage ASC-US/LSIL	M. Arbyn	Belgium
MSS 9-3 • Analytical and clinical performance of the APTIMA® HPV 16, 18/45 genotype assay for detection of HPV 16, 18 and 45 mRNA	S. Joo	USA
MSS 9-4 • Clinical significance of the dynamic profile of type-specific viral load	C. Depuydt	Belgium
MSS 9-5 • Diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: results of a 3 years prospective study	S. Tiews	Germany

### MSS 10 Discover the value of molecular markers

Chair: J. Doorbar – P. Snijders

Forum Hall

18:00 – 19:00

MSS 10-1 • Methylation markers in triage & screening	A. Lorincz	UK
MSS 10-2 • Host gene methylation markers for triage of HPV positive women	P. Snijders	The Netherlands
MSS 10-3 • Altered microRNA expression associated with chromosomal changes in cervical carcinogenesis	R. Steenbergen	The Netherlands
MSS 10-4 • Molecular markers in triage of primary HPV screening	F. Carozzi	Italy
MSS 10-5 • Molecular markers in referral population	J. Cuzick	UK

## SCIENTIFIC SESSIONS

### SS 4 Controversial issues in the field of HPV: how can models help our understanding?

Chair: M. Brisson – M. Jit

North Hall

14:00 – 15:30

SS 4-1	• Introduction	M. Brisson	Canada
SS 4-2	• Male vaccination: is it cost-effective and can it reduce inequities?	J. Bogaards	The Netherlands
SS 4-3	• Cross-protection: how do we interpret trial data, and how important is it at a population level?	T. Malagon	Canada
SS 4-4	• Re-infection: how can it affect the success of HPV vaccine programs?	A. Vink	The Netherlands
SS 4-5	• 2-dose vs. 3-dose HPV vaccination: can a 2-dose strategy be the best use of resources?	M. Jit	UK
SS 4-6	• Serotype replacement: should we be worried?	M.C. Boily	UK

### SS 5 Emerging issues in head and neck cancers

Chair: J. Lacau de Saint Guily – L. Licitra

North Hall

15:30 – 16:30

SS 5-1	• Incidence and risk factors for head and neck cancer and cervical cancer among HIV-infected individuals in North America	G. D'Souza	USA
SS 5-2	• HPV serology and head and neck cancers: new evidence	M. Pawlita	Germany
SS 5-3	• Differences in the epidemiology and risk factors of HPV+ and HPV- head and neck cancers	A. Chaturvedi	USA
SS 5-4	• Differences between HPV+ and HPV- head and neck cancers at the molecular level	R. Brakenhoff	The Netherlands
SS 5-5	• Are we encountering an HPV epidemic of OSCC, the Stockholm data	T. Dalianis	Sweden
SS 5-6	• Treatments for HPV+ vs HPV- disease – should they be different?	L. Licitra	Italy

Coffee Break 16:30 – 17:00

### SS 6 Recent progress and questions related to HPV vaccines

Chair: M. Steben – M. Einstein

North Hall

17:00 – 18:00

SS 6-1	• Quadrivalent vaccine – long-term follow-up studies	M. Steben	Canada
SS 6-2	• Evaluation of HPV type competition in women: an epidemiological approach to address the potential for type replacement post-vaccination	J. Tota	Canada
SS 6-3	• Main challenges in trying to compare both vaccines	P. Bonanni	Italy
SS 6-4	• Unanswered questions from the available clinical studies	E. Franco	Canada
SS 6-5	• Epidemiology and disease burden considerations in future health technology assessments for HPV vaccination in Europe	X. Castellsagué	Spain

### SS 7 Non-cervical HPV associated diseases, current knowledge

Chair: J. Palefsky – C. Lacey

North Hall

18:00 – 19:15

SS 7-1	• HPV, skin and sex	M. Skerlev	Croatia
SS 7-2	• Update on HPV-associated oral cancer in men	A. Chaturvedi	USA
SS 7-3	• New approaches to the treatment of AIN	J. Palefsky	USA
SS 7-4	• Penile HPV infection and disease in HIV-infected men	C. Lacey	UK
SS 7-5	• Female HPV data	R. Crawford	France
SS 7-6	• Economic burden of non-cervical human papillomavirus-related cancers in Western Europe: a scoping review	N. Largeron	France

## SCIENTIFIC SESSIONS

**SS 8 Update on HPV vaccines**

Chair: F. Martinon Torres – A. Szarewski

Terrace 1

14:00 – 15:15

- |        |  |                      |           |
|--------|--|----------------------|-----------|
| SS 8-1 | • Use of HPV prophylactic vaccines in infected persons   | M. Steben            | Canada    |
| SS 8-2 | • HPV vaccination with Cervarix in adult women   | A. Szarewski         | UK        |
| SS 8-3 | • No adverse signals observed after exposure to human papillomavirus type 6/11/16/18 vaccine during pregnancy : 5 years data from the pregnancy registry | F. Lievano           | USA       |
| SS 8-4 | • How best to measure vaccine effectiveness?   | S. Garland           | Australia |
| SS 8-5 | • 48-month efficacy of the HPV-16/18 AS04-adjuvanted vaccine in young Japanese women   | R. Konno             | Japan     |
| SS 8-6 | • Gardasil® and autoimmune disorders: safety assessment using the PGRx information system  | L. Grimaldi-Bensouda | France    |

**SS 9 New horizons in anti-viral drugs and therapeutic vaccine**

Chair: P. Stern – S. van der Burg

Terrace 1

15:15 – 16:30

- |        |   |                 |                 |
|--------|---|-----------------|-----------------|
| SS 9-1 | • Lecture: antiviral agents against HPV: recent advances  | C. Fisher       | USA             |
| SS 9-2 | • Local immune response in HPV induced cancer   | S. Van der Burg | The Netherlands |
| SS 9-4 | • Investigation of the activity of the HIV protease lopinavir against HPV                               | I. Hampson      | UK              |
| SS 9-5 | • Cidofovir/imiquimod for the treatment of VIN  | A. Tristram     | UK              |
| SS 9-6 | • New approaches for second generation HPV vaccines : chimeric p16 <sup>INK4a</sup> -HPV16 L1 particles | F. Faulstich    | Germany         |

Coffee Break 16:30 – 17:00

**SS 10 Recent development in molecular markers**

Chair: A. Lorincz – M. Von Knebel Doeberitz

Terrace 1

17:00 – 18:00

- |         |  |                         |         |
|---------|--|-------------------------|---------|
| SS 10-1 | • P16 <sup>INK4a</sup> immunocytochemistry versus HPV testing for triage of women with ASC-US or LSIL cervical cytology: a systematic review and meta-analysis | M. Arbyn                | Belgium |
| SS 10-2 | • p16/Ki-67 dual-stained cytology using ThinPrep liquid-based cytology, sub-analyses of more than 9,000 PALMS study participants                               | C. Bergeron             | France  |
| SS 10-3 | • Resolution of ASCUS into "Normal" or "LSIL" diagnoses using OncoTect 3Dx with combined morphologic/biomarker parameters and bioinformatics                   | B. Patterson            | USA     |
| SS 10-4 | • Detection and quantification of HPV E7 oncoproteins in cervical smears   | B. Lener                | Austria |
| SS 10-5 | • Validation of the triage value of HPV16 DNA methylation in the CRISP cohort  | A. Brentnall            | UK      |
| SS 10-6 | • The methylome of episomal and integrated HPV 16 genomes in pre-invasive and invasive cervical lesions  | M. Von Knebel Doeberitz | Germany |

**SS 11 New insights in low income countries**

Chair: J. Jeronimo – R. Sankaranarayanan

Terrace 1

18:00 – 19:15

- |         |   |                     |                 |
|---------|---|---------------------|-----------------|
| SS 11-1 | • Rights, ethics and cervical cancer: barriers to prioritizing cervical cancer control in low resource settings                 | J. Cain             | USA             |
| SS 11-2 | • Progress in improvement of cervical cancer prevention in countries of Eastern Europe and Central Asia – triggers and barriers | G. Lazdane          | Denmark         |
| SS 11-3 | • Cost-effectiveness of cervical cancer prevention in the Eastern European region   | H. Berkhof          | The Netherlands |
| SS 11-4 | • HPV RNA testing among high-risk women in Nairobi, Kenya   | J. Smith            | USA             |
| SS 11-5 | • Perspective on treatment of cervical neoplasia in low- and medium-resource countries  | R. Sankaranarayanan | France          |
| SS 11-6 | • How molecular testing will change the way we screen in developing countries   | J. Jeronimo         | USA             |

## FREE COMMUNICATIONS

### FC 8 Cytological screening

Chair: K. Syrjänen – F. Borruto

Klub E (level 1)

14:00 – 15:00

- |        |   |               |                 |
|--------|---|---------------|-----------------|
| FC 8-1 | • Effect of the media on cervical cancer incidence: time-trend analysis of population based cancer registry data and individual screening histories             | P. Sasieni    | UK              |
| FC 8-2 | • Duration of protection offered by cervical screening to women over age 65: evidence from a population-based case-control study of prospectively recorded data | A. Castanon   | UK              |
| FC 8-3 | • The importance of being regular: analysis of cervical screening intervals in New Zealand  | H. Lewis      | New Zealand     |
| FC 8-4 | • Effects of offering more flexible cervical screening options for under and unscreened women in Dumfriesshire, Scotland  | L. Wedisinghe | UK              |
| FC 8-5 | • Increase of CIN detection rates in The Netherlands; is LBC testing the underlying cause?  | K. Rozemeijer | The Netherlands |
| FC 8-6 | • Review of cytology and histopathology as part of the NHS Cervical Screening Program audit of invasive cervical cancers  | A. Castanon   | UK              |
| FC 8-7 | • MCM biomarker over-expression enhances standard liquid-based cytomorphology in detecting CIN2+ cervical disease in women $\leq 35$ years                      | D. Rosenthal  | USA             |
| FC 8-8 | • Screening histories of cervical cancer patients: the effect of using incomplete data  | P.A. Dugué    | Denmark         |

### FC 9 HPV screening

Chair: V. Dalstein – D. Heideman

Klub E (level 1)

15:00 – 16:30

- |         |  |                    |                 |
|---------|--|--------------------|-----------------|
| FC 9-1  | • Clinical validation and reproducibility of Abbott RealTime high-risk HPV test in a screening setting of women $\geq 30$ years old  | E. Burrioni        | Italy           |
| FC 9-2  | • HPV E6 oncoprotein-based platform for detection of cervical pre-cancer and cancer  | J. Schweizer       | USA             |
| FC 9-3  | • HPV testing in primary cervical cancer screening in routine practice – a community-based demonstration study   | M. Chevarie-Davis  | Canada          |
| FC 9-4  | • Increased sensitivity and specificity of HPV E6, E7 mRNA quantification compared to HPV DNA for CIN 3+: results from the Inter-Institutional Study to increase specificity in Cervical Cancer Screening (ISIS Study) | G. Lallas          | Greece          |
| FC 9-5  | • Start-HPV: French HPV-based primary screening pilot program for cervical cancer  | V. Dalstein        | France          |
| FC 9-6  | • Two years of routine primary high-risk HPV screening for cervical cancer in Abruzzo (Italy): results and cost-effectiveness analysis   | V. Maccallini      | Italy           |
| FC 9-7  | • The study of 503 cases of cervical cytology interpreted as atypical squamous cells which cannot exclude high grade squamous intraepithelial lesion (ASC-H)   | L. Geng            | China           |
| FC 9-8  | • Assessing the performance of Cervista HPV HR test in a routine cervical screening population   | H. Keegan          | Ireland         |
| FC 9-9  | • Comparison of HPV DNA testing using cobas <sup>®</sup> 4800 and Pap testing as a method of primary screening for cervical cancer. A multicenter study in Greece  | K. Chatzistamatiou | Greece          |
| FC 9-10 | • How many cases of cervical cancer among young women could have been prevented with a more sensitive screening test?  | I. De Kok          | The Netherlands |
| FC 9-11 | • Benefit of HPV-based primary cervical cancer screening   | G. Sroczynski      | Austria         |
| FC 9-12 | • Evaluation of a new cervical cancer screening protocol with Pap and HPV  | R. Oncins-Torres   | Spain           |

Coffee Break 16:30 – 17:00

## FREE COMMUNICATIONS

<b>FC 10 New challenges in HPV associated head and neck cancers</b>		<b>Klub E (level 1)</b>	
Chair: A. Psyrrri – T. Dalianis		17:00 – 19:00	
FC 10-1	• Molecular biology of HPV-associated HNSCC	A. Psyrrri	Greece
FC 10-2	• Incidence of HPV induced oropharyngeal cancer in Spain and its prognostic significance	L. Cerezo	Spain
FC 10-3	• HLA class I expression and tumor infiltrating CD8+ and FoxP3+ T-cells in HPV+/- tonsillar cancer in relation to disease free survival	T. Ramqvist	Sweden
FC 10-4	• Is HPV16 detection in cervical lymph nodes of oropharyngeal cancer a marker of metastases?	H. Mirghani	France
FC 10-5	• Demographic differences in the prevalence of oral HPV in U.S. adults; cross sectional analysis of NHANES 2009-2010	E. Velasco	USA
FC 10-6	• HPV status alters the miRNA expression in tonsillar cancer	E. Garnaes	Denmark
FC 10-7	• Comparative miRNA profiling in human papillomavirus related head & neck and cervical cancer	C. Lajer	Denmark
FC 10-8	• Validation of a novel diagnostic standard in HPV positive oropharyngeal squamous cell carcinoma	A. Schache	UK
FC 10-9	• HPV detection by PCR in suspected tonsillar lesions: smear-biopsy agreement	B. Vairel	France
FC 10-10	• Oral mucosa exfoliated cells for HPV typing by SPF10 in head and neck cancer	P. Morbini	Italy
FC 10-11	• Human papillomavirus infection and p16 <sup>INK4a</sup> /Ki-67 co-expression in the head and neck squamous epithelium	E. Prigge	Germany
FC 10-12	• HPV/p16 <sup>INK4a</sup> status in squamous cell carcinomas of the oral cavity	M. Reuschenbach	Germany
FC 10-13	• HPV infection in squamous cell carcinomas arising from different mucosal sites of the head and neck region. Different significance of p16 immunohistochemistry	F. Bussu	Italy
FC 10-14	• Prognostic factors including role of HPV in early oropharyngeal carcinomas	G. Psychogios	Germany
FC 10-15	• HPV prevalence and relation to tobacco and alcohol in HNSCC in North-East Italy	A. Del Mistro	Italy
FC 10-16	• The expression profile and diagnostic implication of HPV and p16 in squamous cell carcinoma (SCC) in multiple organs	J. Zhai	USA

**MAIN SCIENTIFIC SESSIONS**
**MSS 11 Heterogeneity of CIN3**

Chair: G. Clifford – D. Harper

**Panorama Hall (level 1)**
**8:00 – 9:30**

MSS 11-1 • HPV-specific natural history	G. Clifford	France
MSS 11-2 • The heterogeneity of CIN3: understanding why not all CIN3 progresses to cancer	M. Stoler	USA
MSS 11-3 • Viral and host markers of CIN3 heterogeneity	N. Wentzensen	USA
MSS 11-4 • Management follow-up	D. Harper	USA
MSS 11-5 • The role of naturally-acquired antibodies and HPV type in the natural history of CIN	X. Castellsagué	Spain

**MSS 12 HPV 16 vs other HR HPV carcinogenic infection: the critical issues**

Chair: S. Franceschi

**Panorama Hall (level 1)**
**9:30 – 11:00**

MSS 12-1 • HPV type distribution by severity of lesion	S. Franceschi	France
MSS 12-2 • Natural history and disease heterogeneity	N. Wentzensen	USA
MSS 12-3 • Cross sectional and longitudinal association with high-grade CIN	G. Ronco	Italy
MSS 12-4 • Combination of findings from screening and in vitro transformation data	P. Snijders	The Netherlands
MSS 12-5 • HPV types in the context of HPV vaccination	J. Dillner	Sweden

**MSS 13 HPV DNA and mRNA testing: highlights from the current research**

Chair: F. Carozzi – C. Clavel

**Panorama Hall (level 1)**
**11:00 – 12:30**

MSS 13-3 • Comparison of APTIMA and HC2 in routine screening in Germany	T. Iftner	Germany
MSS 13-1 • Performance characteristics of a fully automated screening and genotyping HPV test - The BD HPV GT Assay on Viper™ LT	B. Nussbaumer	USA
MSS 13-2 • A large UK hospital's experience with the Hologic Cervista® MTA (Medium Throughput Automation)	K. Hunt	UK
MSS 13-3 • Comparison of APTIMA and HC2 in routine screening in Germany	T. Iftner	Germany
MSS 13-4 • HPV testing in the diagnosis and follow-up of CIN patients: comparison of different methods	M. Sideri	Italy
MSS 13-5 • The HR-HPV testing in follow-up of cytological abnormalities with negative colposcopy	F. Carozzi	Italy
MSS 13-6 • Performance of HPV DNA, E6/E7 mRNA and p16 <sup>INK4a</sup> /Ki-67 protein co-expression as a triage tool for LSIL/ASCUS	C. White	Ireland
MSS 13-7 • Scottish Test of Cure Study - HPV test comparisons (STOCS-H)	H. Cubie	UK

**MSS 14 Emerging issues in HPV genotyping**

Chair: A. Szarewski – W. Huh

**Panorama Hall (level 1)**
**12:30 – 14:00**

MSS 14-1 • PREDICTOR 2 study	A. Szarewski	UK
MSS 14-2 • VALGENT 1: findings from Belgium	C. Depuydt	Belgium
MSS 14-3 • VALGENT 3	M. Poljak	Slovenia
MSS 14-4 • Performance of the <i>digene</i> HPV genotyping PS test for the detection of HPV 16, 18, and 45	H. Thai	USA
MSS 14-5 • Comparison of cobas PCR and HC2 HPV testing in a German routine laboratory	H. Ikenberg	Germany

## SCIENTIFIC SESSIONS

**SS 12 Vaccines in the real life – impact – adverse events**

Chair: A. Chaturvedi – M. Pitts

Terrace 1

8:00 – 9:30

- |         |  |                      |         |
|---------|--|----------------------|---------|
| SS 12-1 | • Population impact after opportunistic quadrivalent HPV vaccination in Sweden 2007-2011                                 | A. Wikström          | Sweden  |
| SS 12-2 | • Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against HPV types associated with genital warts                      | A. Szarewski         | UK      |
| SS 12-3 | • The incidence of anogenital warts in Germany after introduction of HPV vaccination                                     | R. Schulze-Rath      | Germany |
| SS 12-4 | • Incidence of genital warts in Sweden pre and post quadrivalent HPV vaccine availability                                | P. Sparen            | Sweden  |
| SS 12-5 | • Occurrence of adverse events after quadrivalent HPV vaccination in Denmark and Sweden                                  | L. Arnheim-Dahlström | Sweden  |
| SS 12-6 | • Quadrivalent HPV-vaccine population effectiveness on genital warts: a population-based study in over 2.2 million women | A. Leval             | Sweden  |
| SS 12-7 | • Could a 9-valent vaccine make a difference?  | C. Schellenbacher    | Austria |

**SS 13 Advanced topics in immunology and molecular biology**

Chair: M. Pawlita

Terrace 1

9:30 – 11:00

- |         |  |                 |         |
|---------|--|-----------------|---------|
| SS 13-1 | • Lecture: molecular evidence for carcinogenicity of pHR-HPV types in cervical carcinoma                     | M. Pawlita      | Germany |
| SS 13-2 | • Immunogenicity and safety of a candidate tetravalent human oncogenic papillomavirus vaccine                | G. Leroux-Roels | Belgium |
| SS 13-3 | • Relationship between the risk of new HPV-16 infection and naturally-acquired type-specific antibody titres | X. Castellsagué | Spain   |
| SS 13-4 | • Molecular basis of papillomavirus latency  | J. Doorbar      | UK      |
| SS 13-5 | • HPV vaccines update: state of the science immunogenicity of HPV2 vs. HPV4                                  | M. Einstein     | USA     |
| SS 13-6 | • Characterization of the local immune response in cervical and vulvar intraepithelial lesions               | M. Sauer        | Germany |

**SS 14 Quality assessment of HPV testing**

Chair: J. Dillner – H. Cubie

Terrace 1

11:00 – 12:30

- |         |   |            |         |
|---------|---|------------|---------|
| SS 14-1 | • Assessment of competence to undertake HPV testing in a cervical screening programme | H. Cubie   | UK      |
| SS 14-2 | • Role of national HPV reference laboratories   | J. Dillner | Sweden  |
| SS 14-3 | • HPV-cytology correlation as QC for cytology   | M. Arbyn   | Belgium |
| SS 14-4 | • Which HPV DNA tests can be considered as clinically validated                       | T. Iftner  | Germany |

**SS 15 HPV testing methods: recent developments**

Chair: P. Snijders – C. Mougín

Terrace 1

12:30 – 14:00

- |         |  |              |         |
|---------|--|--------------|---------|
| SS 15-1 | • Novel methods of genotyping, using deep sequencing or mass spectrometry  | J. Dillner   | Sweden  |
| SS 15-2 | • Clinical validation of HPV genotyping tests (VALGENT 1)  | M. Arbyn     | Belgium |
| SS 15-3 | • Clinical validation of HPV genotyping tests using the Scottish cervical cytology biobank (VALGENT 2)   | K. Cuschieri | UK      |
| SS 15-4 | • Are all HPV target regions created equal? – a critical look at the commonly used HPV target regions and their influence on assay performance | L. Vaughan   | USA     |
| SS 15-5 | • Validation of the QIA Symphony DSP AXpH DNA system as for PreservCyt® testing on the Hybrid Capture 2 rapid capture system                   | J. Giles     | USA     |
| SS 15-6 | • Comparison of automated extraction vs manual conversion of LBC samples for HC2 HPV testing   | F. Carozzi   | Italy   |
| SS 15-7 | • Effect of mixed infections on the detection of high-risk HPV types   | S. Day       | USA     |



## SCIENTIFIC SESSIONS

### **SS 16 Heterosexual and non-sexual transmission of HPV infection** Terrace 2 8:00 – 9:30

Chair: M. Goodman – X. Castellsagué

- |         |  |                 |       |
|---------|--|-----------------|-------|
| SS 16-1 | • Novel co-factors for heterosexual HPV transmission   | X. Castellsagué | Spain |
| SS 16-2 | • Sources of genital HPV infection   | M. Goodman      | USA   |
| SS 16-3 | • Evidence of anogenital oral transmission   | A. Chaturvedi   | USA   |
| SS 16-4 | • Circumcision to prevent male HPV and HIV infection   | J. Smith        | USA   |
| SS 16-5 | • Opportunities for the prevention of the heterosexual transmission (susceptibility, genetics, immunity) | A.B. Moscicki   | USA   |

### **SS 17 Emerging issues on HPV infection associated to HIV and other STI** Terrace 2 9:30 – 11:00

Chair: J. Smith – S. Garland

- |         |  |              |              |
|---------|--|--------------|--------------|
| SS 17-1 | • Validation of cervical cancer screening methods in HIV positive women from Johannesburg            | C. Firnhaber | South Africa |
| SS 17-2 | • HPV vaccines in HIV infected individuals   | AB. Moscicki | USA          |
| SS 17-3 | • Anal HPV and anal cancer in people with HIV  | A. Grulich   | Australia    |
| SS 17-4 | • HPV vaccines in HIV seropositive individuals   | S. Garland   | Australia    |
| SS 17-5 | • Current status of cervical cancer prevention programs worldwide among HIV seropositive individuals | J. Jeronimo  | USA          |
| SS 17-6 | • HPV oncogene mRNA testing for the detection of anal dysplasia in HIV-infected men                  | U. Wieland   | Germany      |
| SS 17-7 | • HPV increasing the risk of HIV   | J. Smith     | USA          |

### **SS 18 Screening – HPV screening and accurate management of cytology negative HPV positive women** Terrace 2 11:00 – 12:30

Chair: T. Cox – P. Sasieni

- |         |  |                 |                 |
|---------|--|-----------------|-----------------|
| SS 18-1 | • Age issues of HPV screening  | P. Sasieni      | UK              |
| SS 18-2 | • Primary screening scenarios based on baseline data from ATHENA                   | T. Cox          | USA             |
| SS 18-3 | • Triage of HPV-positive women: cytology or HPV genotyping?                        | L. Dillner      | Sweden          |
| SS 18-4 | • Methylation as a triage marker for cytology negative HPV positive women          | R. Steenbergen  | The Netherlands |
| SS 18-5 | • p16/Ki-67 dual-stain as a triage marker for cytology-negative/HPV-positive women | H. Ikenberg     | Germany         |
| SS 18-6 | • Other markers for HPV screening triage   | J. Doorbar      | UK              |
| SS 18-7 | • mRNA as a triage for HPV+ cyto- women  | M. Reuschenbach | Germany         |

## SCIENTIFIC SESSIONS

**SS 19 Contemporary management of HPV associated genital diseases**

Terrace 2

Chair: E. Siegler – M. Roy

12:30 – 14:00

SS 19-1	• The value of random biopsies	T. Cox	USA
SS 19-2	• Leep conisation increases the risk for adverse pregnancy outcome: how much?	M. Jakobsson	Finland
SS 19-3	• Managing CIN3 in pregnancy	E. Siegler	Israel
SS 19-4	• Pap smears classified as atypical glandular cells (AGC) – outcomes and management in pregnancy	J. Slama	Czech Republic
SS 19-5	• An innovative treatment of HPV and cervical neoplasia – safety considerations	V. Dvorak	Czech Republic
SS 19-6	• Long-term follow-up of posterior vestibulectomy in the treatment of localized provoked vestibulodynia	P. Tommola	Finland
SS 19-7	• Agreement between colposcopic impression and histology among hrHPV16 positive women	J. Louwers	The Netherlands
SS 19-8	• Post-colposcopy follow-up of women with negative cervical biopsy – a prospective study	S. Sorbye	Norway
SS 19-9	• Risk of cervical cancer after treatment of cervical intraepithelial neoplasia: role of loss to follow-up	M. Rebolj	Denmark
SS 19-10	• Vaginal intraepithelial neoplasia (VaIN 2/3): comparing clinical outcomes of treatment with intravaginal estrogen	H. Rhodes	USA
SS 19-11	• A hand-held electrical impedance spectroscopy device improves colposcopy performance	J. Tidy	UK

## SATELLITE TRAINING COURSE

### STC 1 Comprehensive colposcopy course + accreditation

Coordinators: A. Singer – T. Freeman-Wang

Klub D (Level 1)

8:00 – 14:00

This is a 6 hour intensive course conducted by 2 highly experienced colposcopists/oncologists. They will present the most up-to-date knowledge relating to colposcopy practice as well as of the management of the cervix and lower genital tract precancer. There will be lectures as well as a very informal interactive tutorial which will be clinically oriented. Topics will range from the basic (i.e. normal cervix) to advanced (i.e. micro-invasion and glandular disease). A CD (PDF format) of all PowerPoint lectures will be given out.

Separate registration required for this course

- Introduction
- The normal cervix: a prerequisite to understand the abnormal cervix
- Update on the pathology of cervical precancer
- Questions
- How do we diagnose cervical precancer; cytology, HPV testing, colposcopy and other methods
- The abnormal cervix; colposcopy and methods of examination  
Video case presentations (Faculty)

#### Coffee Break 10:30 – 10:50

- Microinvasion and glandular cervical disease and other difficult colposcopic examination
- Treatment of cervical precancer; who, why and how
- Questions

#### Coffee and Cake 12:20 – 12:40

- Current practice algorithms
- Case presentation (interactive session); cytology, colposcopy, pathology and treatment
- Summary and close

## SATELLITE TRAINING COURSE

### STC 2 Vulvar diseases course + accreditation

Coordinator: J. Bornstein

Klub C (Level 1)

8:30 – 12:00

The satellite course on vulvar disease has been designed for clinicians who currently treat or diagnose women with cervical and vaginal disease. The faculty will discuss current knowledge of vulvar benign and premalignant disease, from various aspects: pathophysiology, clinical features, histological appearance, and treatment. Common and difficult cases will be presented and discussed

STC 2-1 • Introduction	J. Bornstein	Israel
STC 2-2 • Benign HPV lesions: diagnosis and treatment	M. Hampl	Germany
STC 2-3 • Vulvar pain, etiology and diagnosis	J. Bornstein	Israel
STC 2-4 • VIN – diagnosis, terminology	M. Sideri	Italy
STC 2-5 • VIN – prevention and treatment	E. Joura	Austria
STC 2-6 • Vulvar carcinoma - current treatment	M. Roy	Canada
STC 2-7 • Vulvar pain: surgical and non-surgical treatments	J. Bornstein	Israel
STC 2-8 • Psycho-sexual aspects of vulvar disease	M. Steben	Canada
• Summary and close		

### STC 3 Best practices in publishing clinical and public health research

Coordinator: E. Franco

Room 1.2 (Level 1)

8:30 – 12:00

The objectives of this short course are:

- 1) to provide an overview of principles of good scientific practice as applied to research on human subjects;
- 2) to discuss elements of scientific reasoning that are used in clinical and public health research and mentorship;
- 3) to discuss the process of research communication and publishing;
- 4) to discuss the key features that enhance the quality of a paper and its value to the scientific community;
- 5) to discuss rules of authorship, strategies to avoid conflict, criteria to select journals, and issues to be avoided.

Instruction will be via interactive lecture to take advantage of students' own experiences as authors; emphasis on issues pertaining to study design, ethics, data analysis, scientific integrity, and strategies of communicating and interpreting results of clinical and public health research.

This course is intended for public health practitioners, epidemiologists, and other clinical researchers in the early stages of their careers or those who are switching from clinical or public health practice to research. Public health practitioners and policymakers may also find the contents valuable in understanding the process of scientific research and publishing. Researchers whose mother tongue is not English may find the course particularly helpful in assisting them to navigate the process of preparing, submitting, and revising manuscripts for publication in international biomedical journals.

*Note about the instructor:*

Dr. Eduardo L. Franco, James McGill Professor, Departments of Oncology and of Epidemiology; Interim Chair, Department of Oncology, and Director, Division of Cancer Epidemiology, McGill University, Montreal, Canada.

## POSTERS

### P 1 Epidemiology

- |       |   |                              |
|-------|---|------------------------------|
| P 1-1 | • Distribution of HPV genotypes in women with >CIN2 lesions in Madrid   | ML Mateos Lindemann<br>Spain |
| P 1-2 | • Prevalence of HPV infection among men attending STI clinics in England  | D. Mesher<br>UK              |
| P 1-3 | • Mixed lesions (squamous intraepithelial neoplasia and adenocarcinoma in situ) of the cervix are induced by a single HPV genotype    | O. Reich<br>Austria          |
| P 1-4 | • Prevalence of human papillomavirus in Greek patients with head and neck cancers   | E. Tsimplaki<br>Greece       |
| P 1-5 | • Prevalence of multiple HPV infections in a cohort of Greek women with regards to age and cytology                                   | E. Argyri<br>Greece          |
| P 1-6 | • Genotypic profile of the human papillomavirus in relation to cervical cancer in women of Kinshasa, D.R. Congo                       | C. Ali-Risasi<br>Belgium     |
| P 1-7 | • Molecular epidemiology of HPV and chlamydia trachomatis infections in a cohort of young women in Northern Italy                     | E. Tanzi<br>Italy            |
| P 1-8 | • The prevalence and genotype of human papillomavirus on cervical samples from an Irish female population with external genital warts | S. Cremin<br>Ireland         |

### P 2 Vaccines

- |       |   |                                      |
|-------|---|--------------------------------------|
| P 2-1 | • Monitoring the early impact of young girls quadrivalent HPV vaccination on genital warts in Belgium   | C. Gobbo<br>Belgium                  |
| P 2-2 | • Association between human papillomavirus (HPV) vaccination and migraine   | T. Van't Klooster<br>The Netherlands |
| P 2-3 | • Acceptability of HPV vaccination among underserved mothers for their daughter: analysis by education level  | H. Borne<br>France                   |
| P 2-4 | • HPV vaccination and cervical cancer prevention among girls and women from 14 to 23 years in France: review of practices from a survey realised among GPs. | A. Dahlab<br>France                  |
| P 2-5 | • The vaccine and cervical cancer screen project - first interim analysis   | R. Burden<br>South Africa            |
| P 2-6 | • Potential clinical and economic impact of cross-protection induced by HPV-vaccines in the context of the Italian regions                                  | R. Gasparini<br>Italy                |

## POSTERS

## P 3 HPV testing

- |        |   |                   |                 |
|--------|---|-------------------|-----------------|
| P 3-1  | • HPV detection in urine using consensus and genotyping assays  | K. Cuschieri      | UK              |
| P 3-2  | • Comparison of the RealStar® LR HPV DNA assay detecting LR-HPV-types 6, 11, 42, 43 and 44 using cobas® Z 480 system with Hybrid Capture® 2 test  | S. Tiews          | Germany         |
| P 3-3  | • Effect of glacial acetic acid pre-treatment on the molecular detection of human papillomavirus  | H. Cubie          | UK              |
| P 3-4  | • Distribution of five high-risk human papillomavirus genotypes among women in Montenegro   | D. Vujosevic      | Montenegro      |
| P 3-5  | • Correlations between cervical cytology and human papillomavirus detection by Cervista™ HR HPV test  | M. Galand         | Belgium         |
| P 3-6  | • Hologic Cervista high-risk HPV, as a triage screening tool in the Dutch National cervical screening   | S. Van der Meulen | The Netherlands |
| P 3-7  | • Detection of genetic abnormalities using HPV-FISH technique and smart technologies in carcinoma of the uterine cervix                           | L. Moukova        | Czech Republic  |
| P 3-8  | • Marked differences in HPV genotyping  | E. Padalko        | Belgium         |
| P 3-9  | • Clinical performances of Bio-Rad Dx HR-HPV assay for detection of high-grade cervical intraepithelial neoplasia in women with abnormal cytology | P. Sednaoui       | France          |
| P 3-10 | • Prevalence of high-risk HPV genotypes among women in Algiers, Algeria   | N. Bahoura        | Algeria         |
| P 3-11 | • Effect of Proteinase K Treatment of SurePath L-Pap samples on detection of HPV mRNA   | J. Dockter        | USA             |
| P 3-12 | • Experience of an Italian screening program on HPV-DNA testing in the follow-up of patients treated for high grade CIN.                          | P. Garutti        | Italy           |
| P 3-13 | • The performance of APTIMA HPV and APTIMA HPV 16 18/45 genotype assay  | J. Smahelova      | Czech Republic  |
| P 3-14 | • Clinical utility of HPV testing in LSIL – a revision  | C. Sousa          | Portugal        |
| P 3-15 | • HPV DNA testing and typing in a cohort of 450 women in Greece   | A. Chrysagi       | Greece          |

## P 4 Screening

- |       |   |                   |         |
|-------|---|-------------------|---------|
| P 4-1 | • Cervical liquid-based cytology in a referenced ambulatory of low-resource population in São Paulo county. Association with VaIN and VIN. Data from RODEO study. | A. Longatto-Filho | Brazil  |
| P 4-2 | • Barriers to cervical screening in women who have experienced sexual abuse: an exploratory study   | L. Cadman         | UK      |
| P 4-3 | • Problems of, and prospects for, cervical smear screening in Nigeria   | S. Abdulumumuni   | Nigeria |

## P 5 Vulvar disease and neoplasia

- |       |   |                    |         |
|-------|---|--------------------|---------|
| P 5-1 | • Density and phenotype of local immune cells in vulvar cancers of the anterior fourchette in association with the HPV/p16 status | M. Hampl           | Germany |
| P 5-2 | • Prognostication of vulvar cancer based on p14 <sup>ARF</sup> and HPV status: molecular assessment of transcript and protein     | L. De Brot Andrade | Brazil  |

## POSTERS

### P 6 Oral HPV infection

- |       |   |               |             |
|-------|---|---------------|-------------|
| P 6-1 | • Human papillomavirus (HPV) infection in oral cavity of HIV-positive subjects                                      | M. Martinelli | Italy       |
| P 6-2 | • Recurrent genomic alterations and high-risk HPV with impact on prognosis in oropharyngeal squamous cell carcinoma | D.I. Sun      | South Korea |

### P 7 Economics and modelling

- |       |   |             |        |
|-------|---|-------------|--------|
| P 7-1 | • Cost-effectiveness of short-time high-risk HPV testing by self-sampling in Swedish population based screening for cervical cancer       | E. Östenson | Sweden |
| P 7-2 | • Burden of disease due to non-cervical HPV-related cancers in Spain  | J. Cortes   | Spain  |
| P 7-3 | • A preliminary health and economic analysis of vaccinating boys and girls with quadrivalent human papillomavirus vaccine in France       | R. Marty    | France |
| P 7-4 | • A preliminary health and economic analysis of vaccinating boys and girls with quadrivalent human papillomavirus vaccine in Switzerland. | N. LARGERON | France |
| P 7-5 | • A comparative cost-consequence analysis of bivalent and quadrivalent human papillomavirus vaccines in France                            | X. Bresse   | France |

### P 8 Advocacy, psychology and health education

- |       |   |                    |         |
|-------|---|--------------------|---------|
| P 8-1 | • Cervical cancer in Croatia: the importance of public education campaigns for cervical cancer prevention                                     | N. Miheläiç-Labura | Croatia |
| P 8-2 | • Attitude toward human papillomavirus vaccination among college students   | A. Sukegawa        | Japan   |
| P 8-3 | • Assessment of programs for cervical cancer prevention administered by local governments and local communities in Kanagawa prefecture, Japan | E. Miyagi          | Japan   |
| P 8-4 | • Attitudes towards HPV testing and self-sampling in the cervical screening context: a qualitative study of Hindu women in London             | L. Ashdown-Barr    | UK      |

### P 9 Management

- |       |  |                      |          |
|-------|--|----------------------|----------|
| P 9-1 | • Multicenter study of CINII/III in the Valencian community (VC) (Spain) in 2008: epidemiological, cytological and HPV, colposcopic, treatment and follow-up data at 6 and 12 months | E. Garcia            | Spain    |
| P 9-2 | • The QIASymphony® DSP AXpH DNA system*: fully automated extraction of SurePath™ samples for use in RCS-driven Hybrid Capture® 2   | M. Sprenger-Haussels | Germany  |
| P 9-3 | • HPV Focus 2010 - Evaluation of genital diseases related to HPV in Portuguese women   | D. Pereira da Silva  | Portugal |